Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 1, 2012, Pages 102-106

  Pałucha Poniewiera, Agnieszka ^a   Pilc, Andrzej ^a,b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Acamprosate; CDPPB; MGlu5 receptor; NMDA; Tail suspension test

Indexed keywords

3 CYANO N (1,3 DIPHENYL 1H PYRAZOL 5 YL) BENZAMIDE; ACAMPROSATE; FLUMAZENIL; IMIPRAMINE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; UNCLASSIFIED DRUG;

ALCOHOLISM; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL TEST; MALE; MOUSE; NONHUMAN; TAIL SUSPENSION TEST;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZAMIDES; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HINDLIMB SUSPENSION; IMMOBILITY RESPONSE, TONIC; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; N-METHYLASPARTATE; PYRAZOLES; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; TAURINE;

EID: 84864496278     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.05.015     Document Type: Article

References (40)

1. Attucci S., Carla V., Mannaioni G., Moroni F. Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. Br J Pharmacol 2001, 132:799-806.
2. Awad H., Hubert G.W., Smith Y., Levey A.I., Conn P.J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 2000, 20:7871-7879.
3. Belozertseva I.V., Kos T., Popik P., Danysz W., Bespalov A.Y. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 2007, 17:172-179.
4. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
5. Boothby L.A., Doering P.L. Acamprosate for the treatment of alcohol dependence. Clin Ther 2005, 27:695-714.
6. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005, 29:571-625.
7. Daoust M., Legrand E., Gewiss M., Heidbreder C., DeWitte P., Tran G., et al. Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats. Pharmacol Biochem Behav 1992, 41:669-674.
8. Deschwanden A., Karolewicz B., Feyissa A.M., Treyer V., Ametamey S.M., Johayem A., et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry 2011, 168:727-734.
9. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010, 67:793-802.
10. Doherty A.J., Palmer M.J., Bortolotto Z.A., Hargreaves A., Kingston A.E., Ornstein P.L., et al. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. Br J Pharmacol 2000, 131:239-244.
11. Dölen G., Bear M.F. Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J Physiol 2008, 586:1503-1508.
12. Erickson C.A., Mullett J.E., McDougle C.J. Brief report: acamprosate in fragile X syndrome. J Autism Dev Disord 2010, 40:1412-1416.
13. Gupta T., Syed Y.M., Revis A.A., Miller S.A., Martinez M., Cohn K.A., et al. Acute effects of acamprosate and MPEP on ethanol Drinking-in-the-Dark in male C57BL/6J mice. Alcohol Clin Exp Res 2008, 32:1992-1998.
14. Harris B.R., Prendergast M.A., Gibson D.A., Rogers D.T., Blanchard J.A., Holley R.C., et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002, 26:1779-1793.
15. Ibrahim L., Diazgranados N., Luckenbaugh D.A., Machado-Vieira R., Baumann J., Mallinger A.G., et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1155-1159.
16. Kotlinska J., Bochenski M., Danysz W. N-methyl-D-aspartate and group I metabotropic glutamate receptors are involved in the expression of ethanol-induced sensitization in mice. Behav Pharmacol 2006, 17:1-8.
17. Lejoyeux M., Lehert P. Alcohol-use disorders and depression: results from individual patient data meta-analysis of the acamprosate-controlled studies. Alcohol Alcohol 2011, 46:61-67.
18. Lenze E.J., Skidmore E.R., Begley A.E., Newcomer J.W., Butters M.A., Whyte E.M. Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study. Int J Geriatr Psychiatry 2011, 10.1002/gps.2813.
19. Li X., Need A.B., Baez M., Witkin J.M. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 2006, 319:254-259.
20. Mann K., Kiefer F., Spanagel R., Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008, 32:1105-1110.
21. Mayer S., Harris B., Gibson D.A., Blanchard J., Prendergast M.A., Holley R.C., et al. Acamprosate has no effect on NMDA-induced toxicity but reduces toxicity induced by spermidine or by changing the medium in organotypic hippocampal slice cultures from rat. Alcohol Clin Exp Res 2002, 26:655-662.
22. Naassila M., Hammoumi S., Legrand E., Durbin P., Daoust M. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 1998, 22:802-809.
23. Pałucha A., Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 2007, 115:116-147.
24. Pałucha A., Brański P., Szewczyk B., Wierońska J.M., Kłak.K., Pilc A. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav 2005, 81:901-906.
25. Parsons C.G., Danysz W., Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 1998, 11:523-569.
26. Pierrefiche O., Daoust M., Naassila M. Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network. Neuropharmacology 2004, 47:35-45.
27. Pilc A., Kłodzińska A., Brański P., Nowak G., Pałucha A., Szewczyk B., et al. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 2002, 43:181-187.
28. Pisani A., Gubellini P., Bonsi P., Conquet F., Picconi B., Centonze D., et al. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 2001, 106:579-587.
29. Poleszak E., Wlaź P., Wróbel A., Dybała M., Sowa M., Fidecka S., et al. Activation of the NMDA/glutamate receptor complex antagonizes the NMDA antagonist-induced antidepressant-like effects in the forced swim test. Pharmacol Rep 2007, 59:595-600.
30. Pomierny-Chamioło L., Poleszak E., Pilc A., Nowak G. NMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in mice. Pharmacol Rep 2010, 62:1186-1190.
31. Schwartz T.L., Siddiqui U.A., Raza S., Costello A. Acamprosate calcium as augmentation therapy for anxiety disorders. Ann Pharmacother 2010, 44:1930-1932.
32. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999, 375:31-40.
33. Steru L., Chermat R., Thierry B., Simon P. Tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370.
34. Szewczyk B., Poleszak E., Sowa-Kućma M., Wróbel A., Słotwiński S., Listos J., et al. The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids 2010, 39:205-217.
35. Tatarczyńska E., Kłodzińska A., Chojnacka-Wójcik E., Pałucha A., Gasparini F., Kuhn R., et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 2001, 132:1423-1430.
36. Tu J.C., Xiao B., Naisbitt S., Yuan J.P., Petralia R.S., Brakeman P., et al. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 1999, 23:583-592.
37. Wierońska J.M., Szewczyk B., Brański P., Pałucha A., Pilc A. Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 2002, 23:213-216.
38. Xiao B., Tu J.C., Petralia R.S., Yuan J.P., Doan A., Breder C.D., et al. Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of homer-related, synaptic proteins. Neuron 1998, 21:707-716.
39. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-D aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
40. Zarate C.A., Singh J.B., Quiroz J.A., De Jesus G., Denicoff K.K., Luckenbaugh D.A., et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006, 163:153-155.